Thread Rating:
  • 1 Vote(s) - 5 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Sinophran a Chinese break through vaccine using an old style dead virus
#1
I have never told my wife to not get the vax and when she asked me questions I have told her what I know to the best of my reading ability. She ran her own experiment on the side using feedback from her friends and the reactions to their own vaccination. It has been generally agreed for a long time that the Chinese SINOVAX vaccine had some of the unpleasant side effects we read about with vaccines and it never worked as promised.

Sinopharm has not been widely available but if you have connections it could be had starting about 6 months ago. If you take the time to look up the phase one thru 4 studies I think most will come away impressed.

I do not have much trust in anything coming out of China but I will grudgingly admit they might have done something good for a change. I first looked at the UAE study about Sinopharm which was actually carried out over a year https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351310/ One of the deciding factors (or helped) was the Kings sister who has had cancer like forever took the Sinopharm vaccine and she is doing fine considering..

Quote:Several candidate COVID-19 vaccines were developed from diverse platforms. One of these was the BBIBP-CorV vaccine (also known as the Sinopharm COVID-19 vaccine) which was made by the Chinese state-owned pharmaceutical business Sinopharm in China and adopted by the United Arab Emirates (UAE) (Zhang et al., 2021). Sinopharm COVID-19 vaccine is an inactivated vaccine that introduces a dead copy of SARS-CoV-2 into the body by a two-dose schedule, with 14 or 21 days between the 2 doses. By inserting the vaccine dose intramuscularly, the dead antigens from the virus are employed to make antibodies that prepare the immune system for future attacks by the virus. (Xia et al., 2021). The traditional inactivated whole-virus vaccines do not lead to clinical disease. In this technology, the inactivated viruses maintain their ability to replicate in vivo with mild or no symptoms (Forni and Mantovani, 2021).
Phases 1 and 2 of the clinical trials for the Sinopharm COVID-19 vaccine were carried out in China over 1 trial for each phase. A total enrolment of 640 participants showed that the vaccine triggered a COVID-19 neutralizing antibody response with a low rate of adverse reactions. The most common side effects were fever and pain at the site of injection and fever; however, these were mild and self-limiting and did not require treatment (Sharma et al., 2020). Phase 3 was carried out over 4 trials in the following countries: the UAE, Bahrain, Egypt, Jordan, Peru and Argentina, with a total 69 000 people enrolled. The UAE approved the vaccine on December 9, 2020; the UAE announced that the vaccine was 86% efficacious, according to the interim results of its phase 3 trial (Xia et al., 2021).
Having administered over 2 million doses of the vaccine as of mid-January 2021, the UAE Ministry of Health reported the vaccine to be 100% effective in preventing mild and severe COVID-19 cases (China to run human coronavirus vaccine trial in UAE 2020, Development of an Inactivated Vaccine Candidate, 2021, Cyranoski, 2020, Zahid et al., 2021). Moreover, the World Health Organization (WHO) announced that most side effects of the Sinopharm COVID-19 vaccine in 3 clinical trials on 16 671 participants aged 18–59 years were mild to moderate, with headache, fatigue, and injection site reactions being the most common (World Health Organization (WHO) 2021).
Published data to support adverse reactions to the Sinopharm COVID-19 vaccine are lacking. Only 2 studies focus on this vaccine (Hatmal et al., 2021, Jayadevan et al., 2021), and fear of the new vaccine is a driver of vaccine hesitancy (Riad et al., 2021).
Knowledge on what happens post-vaccination among the general population is still limited. Describing what to expect after the first and second dose of vaccination will help lower apprehension about this type of vaccine, increase public confidence in vaccine safety, and accelerate the vaccination process against COVID-19 (Hatmal et al., 2021, Jayadevan et al., 2021). The results of this study will be reassuring to those who are fearful of the Sinopharm COVID-19 vaccine. Therefore, the goal of this study was to provide evidence on Sinopharm COVID-19 vaccine side effects after receiving the first and second dose, as approved by the UAE.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351310/

Quote:Sinopharm BIBP COVID-19 vaccine From Wikipedia, the free encyclopedia

[exnews]The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[1] the Sinopharm COVID-19 vaccine,[2] or BIBP vaccine,[2][3][4] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products,[5] resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[6] BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[7] Its product name is SARS-CoV-2 Vaccine (Vero Cell),[8][9][10] not to be confused with the similar product name of CoronaVac.[11][12]  Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[13] In December 2020, the UAE previously announced interim results showing 86% efficacy.[14]  While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BBIBP-CorV could be transported and stored at normal refrigerated temperatures.[15]  BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[16][17][18] Africa,[19][20][21] South America,[22][23][24] and Europe.[25][26][27] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[28] By May, Sinopharm had supplied 200 million doses.[29] [/exnews]
I had covid in December 2019 so I supposedly have natural immunity. Evidently some well meaning idiots in many countries will not take the natural immunity card as sufficient so.....If it becomes a problem (unless my wife vapor locks ) this will be the vaccine I will be receiving 
Sinopharm vaccine is the way the smallpox and polio vaccines worked to my knowledge..... I had both... It takes longer to manufacture so go figure ... Like I have said China is pretty far down on my list of trust but I assume the Hisos in China have been taking the vaccine for at least a year if not longer... The clinical studies are very promising...at least no reported blood clots killing people so far.


Messages In This Thread
Sinophran a Chinese break through vaccine using an old style dead virus - by 727Sky - 09-30-2021, 12:41 PM

Forum Jump:


Users browsing this thread: 1 Guest(s)